{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:29:29Z","timestamp":1790173769882,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ejca.2017.05.015","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T02:30:38Z","timestamp":1497580238000},"page":"106-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis"],"prefix":"10.1016","volume":"81","author":[{"given":"Antonis","family":"Valachis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav J.","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2017.05.015_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2017.05.015_bib2","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.1074\/jbc.M212929200","article-title":"Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen activated protein kinase kinase (MAPKK) signaling","volume":"278","author":"Govindarajan","year":"2003","journal-title":"J Biol Chem"},{"issue":"26","key":"10.1016\/j.ejca.2017.05.015_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"9839","key":"10.1016\/j.ejca.2017.05.015_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2017.05.015_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2017.05.015_bib7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2017.05.015_bib8","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.05.015_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases","volume":"50","author":"Aurilio","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clon.2014.09.014","article-title":"Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer","volume":"27","author":"Wang","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ejca.2017.05.015_bib11","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1038\/srep08065","article-title":"Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases","volume":"5","author":"Mao","year":"2015","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.ejca.2017.05.015_bib12","doi-asserted-by":"crossref","first-page":"e70826","DOI":"10.1371\/journal.pone.0070826","article-title":"Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing","volume":"8","author":"Boursault","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejca.2017.05.015_bib13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/modpathol.2014.136","article-title":"Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy","volume":"28","author":"Bradish","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2017.05.015_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1479-5876-11-202","article-title":"Heterogeneous distribution of BRAF\/NRAS mutations among Italian patients with advanced melanoma","volume":"11","author":"Colombino","year":"2013","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.ejca.2017.05.015_bib15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"issue":"5","key":"10.1016\/j.ejca.2017.05.015_bib16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjd.12504","article-title":"The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort","volume":"169","author":"Ekedahl","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2017.05.015_bib17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamadermatol.2014.3689","article-title":"BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases","volume":"151","author":"Eriksson","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/path.4318","article-title":"Molecular and genetic diversity in the metastatic process of melanoma","volume":"233","author":"Harbst","year":"2014","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2017.05.015_bib19","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J Carcinog"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdermsci.2016.10.006","article-title":"Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: a clue for intra- and inter-tumor heterogeneity","volume":"85","author":"Kaji","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"5","key":"10.1016\/j.ejca.2017.05.015_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2340\/00015555-2326","article-title":"Highly concordant results between immunohistochemistry and molecular testing of mutated V600E BRAF in primary and metastatic melanoma","volume":"96","author":"Manfredi","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.ejca.2017.05.015_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient homogeneity of BRAFV600E expression in melanoma","volume":"38","author":"Menzies","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ejca.2017.05.015_bib24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/CMR.0000000000000166","article-title":"BRAF mutation screening in melanoma: is sentinel lymph node reliable?","volume":"25","author":"Nardin","year":"2015","journal-title":"Melanoma Res"},{"issue":"17","key":"10.1016\/j.ejca.2017.05.015_bib25","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2017.05.015_bib26","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1038\/jid.2015.229","article-title":"Intra- and inter-tumoral homogeneity of BRAF(V600E) mutations in melanoma tumors","volume":"135","author":"Riveiro-Falkenbach","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2017.05.015_bib27","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/jid.2013.378","article-title":"Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?","volume":"134","author":"Saint-Jean","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.05.015_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.yexmp.2014.09.008","article-title":"Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy","volume":"97","author":"Saroufim","year":"2014","journal-title":"Exp Mol Pathol"},{"issue":"35","key":"10.1016\/j.ejca.2017.05.015_bib29","doi-asserted-by":"crossref","first-page":"37895","DOI":"10.18632\/oncotarget.5634","article-title":"Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma","volume":"6","author":"Satzger","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ejca.2017.05.015_bib30","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","article-title":"Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas","volume":"10","author":"Shinozaki","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.ejca.2017.05.015_bib31","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1097\/MD.0000000000000285","article-title":"BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article","volume":"93","author":"Verlinden","year":"2014","journal-title":"Med Baltim"},{"issue":"2","key":"10.1016\/j.ejca.2017.05.015_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/DAD.0000000000000404","article-title":"BRAF-V600 mutation heterogeneity in primary and metastatic melanoma: a study with pyrosequencing and immunohistochemistry","volume":"38","author":"Yaman","year":"2016","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib33","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E)) mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.ejca.2017.05.015_bib34","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2017.05.015_bib35","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/bjd.12248","article-title":"BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel","volume":"168","author":"Gonzalez","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2017.05.015_bib36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.sder.2012.07.007","article-title":"Molecular platforms utilized to detect BRAF V600E mutation in melanoma","volume":"31","author":"Curry","year":"2012","journal-title":"Semin Cutan Med Surg"},{"issue":"10","key":"10.1016\/j.ejca.2017.05.015_bib37","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/bjc.2013.143","article-title":"Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice","volume":"108","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2017.05.015_bib38","doi-asserted-by":"crossref","first-page":"e35309","DOI":"10.1371\/journal.pone.0035309","article-title":"Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials","volume":"7","author":"Lovly","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jmoldx.2012.08.003","article-title":"Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas","volume":"15","author":"Lade-Keller","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ejca.2017.05.015_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1479-5876-12-117","article-title":"Discrepant alterations in main candidate genes among multiple primary melanomas","volume":"12","author":"Colombino","year":"2014","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00008390-200502000-00013","article-title":"Melanoma of unknown primary: experience at Massachusetts general Hospital and Dana-Farber Cancer Institute","volume":"15","author":"Katz","year":"2005","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.ejca.2017.05.015_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.04.007","article-title":"Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature","volume":"78","author":"Kamposioras","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.ejca.2017.05.015_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archderm.142.4.433","article-title":"Multiple primary melanoma: two-year results from a population-based study","volume":"142","author":"Titus-Ernstoff","year":"2006","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.ejca.2017.05.015_bib44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/archderm.139.8.1013","article-title":"Enhanced survival in patients with multiple primary melanoma","volume":"139","author":"Doubrovsky","year":"2003","journal-title":"Arch Dermatol"},{"issue":"17","key":"10.1016\/j.ejca.2017.05.015_bib45","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1002\/cncr.27407","article-title":"Single versus multiple primary melanomas: old questions and new answers","volume":"118","author":"Hwa","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2017.05.015_bib46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6606072","article-title":"Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression","volume":"104","author":"Lin","year":"2011","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2017.05.015_bib47","doi-asserted-by":"crossref","first-page":"e111153","DOI":"10.1371\/journal.pone.0111153","article-title":"Clonal architectures and driver mutations in metastatic melanomas","volume":"9","author":"Ding","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejca.2017.05.015_bib48","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1535-7163.MCT-12-0530","article-title":"Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine","volume":"11","author":"Wilmott","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.015_bib49","doi-asserted-by":"crossref","first-page":"e85004","DOI":"10.1371\/journal.pone.0085004","article-title":"Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma","volume":"9","author":"Menzies","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2017.05.015_bib50","first-page":"340","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","author":"Riley","year":"2010","journal-title":"BMJ"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491730967X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491730967X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T21:50:01Z","timestamp":1535752201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491730967X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":50,"alternative-id":["S095980491730967X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.05.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}